A study evaluating efficacy of [18F]fluorothymidine- identified active bone marrow sparing for pelvic cancer patients treated with chemoradiation therapy.
Phase of Trial: Phase IV
Latest Information Update: 26 Jul 2017
At a glance
- Drugs F-18 fluorothymidine (Primary)
- Indications Pelvic cancer
- Focus Diagnostic use
- 26 Jul 2017 New trial record